|
|
| The ENZAMET Clinical Trial For Prostate Cancer Awarded 2020 ACTA Trial of the Year
|
|
|
| The Australian Clinical Trials Alliance (ACTA) has recognized the remarkable Australians who advance the health system through clinical trials at the virtual Clinical Trials 2020: National Tribute and Award Ceremony. This year, one trial scooped the pool at the awards. The winner of the 2020 ACTA Trial of the Year Award, the ACTA STInG Award for Excellence in Trial Statistics and the Consumer Involvement Award was the ENZAMET Trial. |
|
|
|
|
|
| ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial
|
| Ian Davis, MBBS, Ph.D., FRACP, FAChPM
|
| Drs. Ian Davis, Arun Azad, and Lisa Horvath provided an update on the critical Phase III ENZAMET trial recapping the 2019 publication before presenting immuno-metabolic biomarkers to predict response to enzalutamide in men with mHSPC, what’s coming next for the ENZAMET trial from the perspective of genomic and transcriptomic analysis, and additional data to come including the publication of the HRQL data.
|
|
|
|
|
|
| Choosing First-Line Systemic Therapy for Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
|
| Alicia Morgans, MD, MPH
|
(Original Manuscript)
Metastatic hormone-sensitive prostate cancer (mHSPC) has become increasingly prevalent in the United States. Between 2009 and 2020, experts have projected a nearly 17% increase in the number of newly diagnosed mHSPC cases and a more than 18% increase in cases of mHSPC occurring after failure of local (curative-intent) treatment.
|
|
|
|
|
|
|
|
|
|
|
| Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
|
| Christopher Sweeney, MBBS
|
| At the last Advanced Prostate Cancer Consensus Conference, Christopher Sweeney, MBBS, presented on systemic therapy for prostate cancer and the vast spectrum of patients starting ADT for metastatic disease. He reviews the available treatment options in this disease space and the effect of these treatments on overall survival.
|
|
|
|
|
|
| Treatment Selections in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape
|
| Dana Rathkopf, MD
|
| At the 2020 ASCO Genitourinary Cancers Symposium, Dana Rathkopf discussed two oral presentations: 1) Time to second progression (PFS2) in patients from TITAN with metastatic castration-sensitive prostate cancer by first subsequent therapy (hormonal versus taxane) and 2) Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer: A correlative study of E3805 CHAARTED.
|
|
|
|
|
|
| Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective - Beyond the Abstract
|
| Kenrick Ng, MD
|
| This article is co-authored by a patient with metastatic hormone-sensitive prostate cancer who is receiving abiraterone and androgen deprivation therapy treatment and three healthcare professionals. It offers a tripartite view of issues regarding the management of advanced prostate cancer. The patient relates his personal experiences struggling with the diagnosis, his experience with treatment and the physical, emotional and psychosexual impact on his life.
|
|
|
|
|
|
| Impact of Baseline Serum IL-8 on Metastatic Hormone-Sensitive Prostate Cancer Outcomes in the Phase 3 CHAARTED Trial (E3805) - Beyond the Abstract
|
| Anis Hamid, MD and Christopher Sweeney, MBBS
|
| In recent years, large randomized Phase III clinical trials have demonstrated significant prolongation in overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) by combining agents to the long-held standard of androgen deprivation therapy. Despite these advances, mHSPC remains a lethal disease with a typical life expectancy of fewer than five years. Leveraging serum samples from the phase 3 CHAARTED trial of patients treated with ADT +/- docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC), the authors of this study validated these findings.
|
|
|
|
|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer, The ENZAMET Trial
|
Tanya B. Dorff, MD
Tanya Dorff and Alicia Morgans discuss the ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer) trial design and the effects of adding enzalutamide to first-line treatment that included testosterone suppression with or without early docetaxel.
|
|
|
|
|
|
|
|
|
 |
|
| The Impact of Academic Collaborations in mHSPC: The ENZAMET Trial |
Christopher Sweeney, MBBS
Chris Sweeney and Alicia Morgans discuss the academic collaboration for the ENZAMET Trial, first initiated in November 2014. A global collaborative investigator-initiated trial led by ANZUP Cancer Trials Group and sponsored by the University of Sydney, in collaboration with Canadian Cancer Trials Group, Dana-Farber Cancer Institute, and Cancer Trials Ireland. |
|
|
|
|
|
|
|
|
|
|
Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial
|
Hannah Rush, MBChB
Hannah Rush joins Alicia Morgans in a conversation about the quality of life outcomes reported in patients receiving docetaxel or abiraterone in the STAMPEDE trial.
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer
|
|
Evan Yu, MD
|
| Evan Yu presents the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. He details the most crucial studies to date demonstrating improved overall survival in mHSPC patients, including the ARCHES, ENZAMET, STAMPEDE, and TITAN clinical trials.
|
|
|
|
|
|
|
|
|
|
|
